Present in many 'fat burners', often alongside caffeine.
Small effect on metabolism, with added cardiovascular risk.
View the study (review) →⏱ 3 min read
Synephrine, also called p-synephrine to distinguish it from the synthetic isomers that do not occur in nature, is the active principle of bitter orange (Citrus aurantium), a fruit whose extract became popular in the fat-burner industry starting in 2004, just when ephedrine was banned by the FDA for its dangerous cardiovascular profile, and the industry was urgently looking for a commercially viable substitute to fill the same niche.
Structurally, synephrine is very similar to ephedrine and adrenaline, which explains why it activates beta-3 adrenergic receptors in adipose tissue and modestly increases energy expenditure and lipolysis; the problem is that it also activates cardiac alpha and beta receptors, although less potently, which keeps a lower cardiovascular risk profile than ephedrine but not a null one, especially when combined with caffeine or other stimulants.
The available meta-analyses on synephrine in humans describe a very modest effect on energy expenditure, on the order of 65 additional kilocalories per day at doses of 50 milligrams, and an effect on fat loss that in short-term trials is statistically significant but clinically smaller than that of a morning of brisk walking, which puts in perspective the real usefulness of the compound when compared with lifestyle interventions that carry no associated cardiovascular risk.
Most commercial products do not contain synephrine alone, but combinations with caffeine, green tea extract, yohimbine, capsaicin, and other stimulants, and it is precisely these combinations that have generated the most adverse reports in pharmacovigilance registries, including cases of sudden hypertension, arrhythmias, heart attacks, and cerebrovascular events in young people with no prior risk factors.
Although isolated synephrine at low doses does not appear to raise heart rate or blood pressure to a clinically significant degree in healthy people, high doses and, above all, combinations with caffeine do, and that is the reality of most products on the market: synephrine is rarely sold alone in standardized capsules; it is almost always part of multi-ingredient formulas designed to maximize the subjective effect of the stimulant, which makes it difficult to assess safe doses and real efficacy.
People with hypertension, arrhythmias, ischemic heart disease, anxiety, pregnancy, breastfeeding, or those taking MAOI antidepressants or certain antiarrhythmics should avoid it completely; in athletes, moreover, synephrine is in a gray zone in some anti-doping codes, and it is advisable to check each federation's regulations before taking it, especially in international competitions where controls may be stricter than expected.
If the goal is sustainable fat loss, the available evidence does not support the use of synephrine as a primary tool: the effect on energy expenditure is small, the effect on body composition in the medium term is marginal, and the added cardiovascular risk, although low in absolute terms, is real and entirely avoidable when alternatives with better evidence and without that burden exist.
Strength training with sufficient protein intake, a moderate calorie deficit sustained over time, and regular aerobic exercise remain the tools with the best balance of efficacy, safety, and sustainability for reducing body fat, and no commercial supplement has shown on its own that it can match the impact these three pillars produce when applied consistently for months.
Information, not medical advice. Scientific evidence reflects the quality of the studies.